Equities

Appili Therapeutics Inc

APLI:TOR

Appili Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.035
  • Today's Change0.00 / 0.00%
  • Shares traded27.15k
  • 1 Year change0.00%
  • Beta1.1419
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

  • Revenue in CAD (TTM)1.15m
  • Net income in CAD-5.34m
  • Incorporated2015
  • Employees8.00
  • Location
    Appili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
  • Phone+1 (902) 442-4655
  • Fax+1 (902) 442-4655
  • Websitehttps://appilitherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eve & Co Inc7.77m-5.92m3.74m--------0.4817-0.2055-0.20550.26980.7330.15190.74938.73---11.58---24.24---3.10---76.22--0.062-5.050.4892--2.94---71.97------
Appili Therapeutics Inc1.15m-5.34m4.25m8.00------3.70-0.044-0.0440.0095-0.08110.5047--2.12---234.31-117.41---173.66-----464.23-3,037.15---5.32-----75.97--63.20---43.04--
Entourage Health Corp40.71m-46.17m4.61m251.00------0.1132-0.150-0.1500.1324-0.47761.052.8412.12---118.59-55.14---150.9213.37-40.59-113.40-199.990.0893-0.807311.31---0.43838.6262.51---49.49--
Innovotech Inc1.18m-157.59k4.69m16.00--5.03--3.96-0.004-0.0040.03040.02390.96966.625.51---12.922.90-15.523.5668.6371.56-13.332.192.82--0.00--5.057.42-15.43--35.69--
StageZero Life Sciences Ltd4.08m-17.07m4.92m40.00------1.21-0.1609-0.16090.0377-0.100.671722.8748.05101,923.90-281.22-135.76----0.3457-2.74-418.64-246.920.0329-14.74-----25.1255.93-52.53------
Principal Technologies Inc581.16k-1.52m4.94m----6.07--8.49-0.0657-0.06570.02570.02470.577--3.71---147.50---286.94--42.98---255.65-----59.800.0757--25.43--23.53------
Data as of May 16 2024. Currency figures normalised to Appili Therapeutics Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.